This announcement is a separate document:
宏源药业：关于2023年度计提信用减值损失及资产减值损失的公告
Hongyuan Pharmaceutical: Announcement on Accruing Credit Impairment Losses and Asset Impairment Losses in 2023
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.